Tarsus Pharmaceuticals (TARS) Revenue & Revenue Breakdown
Tarsus Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$451.36M
Latest Revenue (Q)
$118.70M
Main Segment (Y)
Product
Tarsus Pharmaceuticals Revenue by Period
Tarsus Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $451.36M | 146.71% |
| 2024-12-31 | $182.95M | 948.62% |
| 2023-12-31 | $17.45M | -32.42% |
| 2022-12-31 | $25.82M | -54.73% |
| 2021-12-31 | $57.03M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Tarsus Pharmaceuticals generated $451.36M in revenue during NA 2025, up 146.71% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $118.70M | 15.62% |
| 2025-06-30 | $102.66M | 31.05% |
| 2025-03-31 | $78.33M | 17.96% |
| 2024-12-31 | $66.41M | 38.01% |
| 2024-09-30 | $48.12M | 17.90% |
| 2024-06-30 | $40.81M | 47.80% |
| 2024-03-31 | $27.61M | 111.18% |
| 2023-12-31 | $13.08M | 598.88% |
| 2023-09-30 | $1.87M | 100.00% |
| 2023-06-30 | - | -100.00% |
| 2023-03-31 | $2.50M | -75.00% |
| 2022-12-31 | $10.00M | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $15.28M | 2734.32% |
| 2022-03-31 | $539.00K | 59.47% |
| 2021-12-31 | $338.00K | -72.74% |
| 2021-09-30 | $1.24M | -94.37% |
| 2021-06-30 | $22.02M | -34.14% |
| 2021-03-31 | $33.43M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Tarsus Pharmaceuticals generated $118.70M in revenue during Q3 2025, up 15.62% compared to the previous quarter, and up 290.83% compared to the same period a year ago.
Tarsus Pharmaceuticals Revenue Breakdown
Tarsus Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Product | $451.36M | $180.06M | $14.73M | - | - |
| License Fees and Collaboration | - | $2.89M | $2.72M | $955.00K | $2.08M |
| Collaboration Revenue | - | - | - | $1.92M | $3.96M |
| License and Service | - | - | - | $23.89M | $53.07M |
Tarsus Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $151.67M | $118.70M | $102.66M | $78.33M | $107.22M | $48.12M | $24.72M | $13.08M | $1.65M | - | - | - | - | - | - | - |
| License And Collaboration | - | - | - | - | - | - | $2.89M | $218.00K | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - | - |
| License and Service | - | - | - | - | - | - | - | - | - | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
| Collaboration | - | - | - | - | - | - | - | - | - | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product (100.00%).
Tarsus Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|
| License And Collaboration | $2.50M | $522.00K | $33.00K | $65.00K | $737.00K | $1.30M | - |
| License and Service | - | $10.00M | $13.89M | - | $708.00K | $19.05M | $33.31M |
| Collaboration | - | - | $1.38M | $539.00K | $532.00K | $2.97M | $121.00K |
Tarsus Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: License And Collaboration (100.00%).
Tarsus Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AAPG | ASCENTAGE PHARMA GROUP | $980.65M | $141.22K |
| TVTX | Travere Therapeutics | $490.73M | $164.86M |
| ZLAB | Zai Lab | $460.16M | $116.09M |
| TARS | Tarsus Pharmaceuticals | $451.36M | $118.70M |
| ARQT | Arcutis Biotherapeutics | $376.07M | $99.22M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| ADPT | Adaptive Bio | $276.98M | $58.88M |
| CGON | CG Oncology | $4.04M | $1.67M |
| IRON | Disc Medicine | - | $7.91M |
| SRRK | Scholar Rock | - | - |
| CELC | Celcuity | - | $154.00K |